Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems. Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/12 | $51,000,000 | Series E |
Aurora Funds Baxter Ventures Caxton Advantage Life Sciences Fund Domain Associates Edmond de Rothschild Investment Partners Quaker Partners RusnanoMedInvest | undisclosed |
